CHA Biotech announced that it will participate in the ‘2023 JP Morgan Healthcare Conference’ to be held in San Francisco, USA from January 9 (Monday) to January 12 (Thursday, local time), 2023.
CHA Biotech plans to introduce the pipeline it is currently focusing on in one-on-one meetings with overseas pharmaceutical and bio companies and discuss technology transfer, joint development, and investment attraction.
The pipeline that CHA Biotech is focusing on is ▲anticancer immune cell therapy ‘CBT101’ ▲cell therapy for chronic back pain caused by degenerative lumbar intervertebral discs ‘CordSTEM-DD’ ▲ovarian dysfunction cell therapy ‘CordSTEM-POI’ ▲Parkinson’s disease cell therapy ‘CBT’ -NPC’.
In particular, we are planning meetings with about 30 global pharmaceutical companies, so we expect to have in-depth discussions on partnerships.
“Many global pharmaceutical and bio companies are showing interest in CHA Biotech’s cell therapy pipeline,” said Yang Eun-young, head of CHA Biotech’s strategic BD division. “We will do our best to expand business opportunities.”
Meanwhile, the JP Morgan Healthcare Conference is the world’s largest healthcare investment event, with over 1,500 pharmaceutical and bio companies from over 50 countries participating every year.
→ Go to ‘Asia Innovation Hub Pangyo Techno Valley 2022’ news